HTN Management and Cardiovascular Adverse Event Prevention in B-Cell Malignancies Undergoing BTKi
Overview
Tab Title Description
Study type
ObservationalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Rochester, Minnesota: 23-007083
NCT ID: NCT06151730
Sponsor Protocol Number: 23-007083
About this study
The purpose of this study is to prospectively define the incidence of new and/or worsening hypertension in patients with B-cell malignancies on Bruton Tyrosine Kinase Inhibitors.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:
- Patients with:
- Chronic lymphocytic leukemia (CLL)[;
- Mantle cell lymphoma (MCL);
- Waldenstrom macroglobulinemia (WM);
- Mantle cell lymphoma (MCL);
- marginal zone lymphomas (MZL).
- To begin bruton tyrosine kinase inhibitors (BTKi)treatment (either as a single agent or on combination with others), who are willing to return to Mayo Clinic for ongoing follow-up.
Exclusion Criteria:
- Patients with known CNS involvement of their B cell malignancy.
Note: Other protocol defined Inclusion/Exclusion Criteria may apply.
Eligibility last updated 7/20/23. Questions regarding updates should be directed to the study team contact.
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
| Mayo Clinic Location |
Status |
Contact |
Rochester, Minn.
Mayo Clinic principal investigator Joerg Herrmann, M.D. |
Open for enrollment |
Contact information:
Cancer Center Clinical Trials Referral Office
(855) 776-0015
|
More information
Publications
Publications are currently not available